[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"macular-degeneration-dry\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:macular-degeneration-dry":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100356509","retinal-photoreceptor-outer-segment-length-before-and-after-light-stimulation---a-pilot-study-100356509",false,"NCT03921931","Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study","Assessment of Retinal Photoreceptor Outer Segment Length With Optical Coherence Tomography Before and After Light Stimulation - a Pilot Study","Inclusion Criteria:\n\n* men and women aged over 18 years\n* signed informed consent form\n* ametropia below 3 diopters\n* ability and willingness to follow instructions\n\nfor healthy volunteers:\n\n* normal ophthalmologic findings\n\nfor primary open angle glaucoma patients (POAG):\n\n* diagnosed POAG\n* MD \\\u003C= 10 dB\n\nfor age-related macular degeneration (AMD):\n\n* diagnosed dry AMD\n* diagnosed stage II or stage III AMD\n\nExclusion Criteria:\n\n* Presence of any abnormalities preventing reliable measurements\n* Ocular inflammation and ocular disease interfering with the study aims\n* Use of photosensitizing medication (phototoxic drugs, photoallergic drugs) in the 3 months preceding the study\n* Presence of any condition with the possibility of causing photosensitivity, including systemic lupus erythematosus SLE, Porphyria, Vitiligo, Xeroderma Pigmentosum and Albinism\n* Presence of any form of epilepsy\n* Ocular surgery in the 3 months preceding the study\n* Pregnancy, planned pregnancy or lactating\n* Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease",true,"ALL","18 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","It has been shown that reactions of human retinal photoreceptors to a light stimulus can be measured with custom-made, research prototype optical coherence tomography (OCT) systems. This can be used as a biomarker for the function of the photoreceptors. Due to the high technical demands on the system, however, the technique is currently not available for clinical purposes. In this pilot study a protocol to measure changes in retinal photoreceptor layer thickness before and after light stimulation shall be developed based on a commercial OCT system and newly developed algorithms. Other variables, such as circadian processes shall be investigated as well. After measurements in healthy volunteers, the protocol is planned to be applied in patients with primary open angle glaucoma (POAG) and age-related macular degeneration (AMD) to test for feasibility of the method in these patient groups.",[27,28],"Macular Degeneration, Dry","Primary Open-angle Glaucoma",[30,31,32,33,34,35],"light stimulation","retinal photoreceptors","light adaptation","functional optical coherence tomography","optophysiology","intrinsic optical signals","RECRUITING","2025-05-13",{"date":39,"type":40},"2025-05-16","ACTUAL",{"date":42,"type":40},"2018-11-26",{"date":44,"type":21},"2026-05-31",{"name":46,"class":47},"Medical University of Vienna","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100427563","subthreshold-laser-treatment-for-reticular-pseudodrusen-secondary-to-age-related-macular-degeneration-100427563","NCT04847635","Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration","PASCAL-RPD","Inclusion Criteria:\n\n* 50 years or older\n* Presence of RPD secondary to AMD\n* Best-corrected visual acuity (BCVA) between 20\u002F20 and 20\u002F400 inclusive\n* Clear ocular media\n* Ability to provide informed consent and attend all study visits\n\nExclusion Criteria:\n\n* Presence of Geographic Atrophy (GA)\n* Evidence of choroidal neovascularization in either eye\n* Any prior treatment for AMD, aside from antioxidants\n* Any corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures\n* Aphakic eye with vitreous in the anterior chamber\n* Neovascular Glaucoma\n* Glaucoma caused by congenital angle anomalies\n* Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner\n* Significant corneal edema or reduced water clarity that obscures the view angle in detail\n* Glaucoma secondary to active uveitis\n* Any other ocular condition that would progress in the study period and confound visual acuity assessment\n* Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve Presence of idiopathic or autoimmune-associated uveitis\n* Any intraocular surgery 3 months of entry\n* Any prior thermal laser in the macula\n* History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery\n* Previous therapeutic radiation in the ocular region in either eye\n* Any treatment with an investigational agent in the previous 60 days before study entry\n* Women of child-bearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization (further definition can be found in Section 12.7) at Baseline, unless they are using highly effective methods of contraception during dosing of study treatment.\n* Participation in an investigational drug, biologic, or device study within 6 Months prior to Baseline \\[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary","55 Years",{"count":58,"type":21},50,[24],"Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.\n\nThe objective of this study is to establish the effectiveness of subthreshold laser treatment in increase\u002Fprevent the decrease of the retinal sensibility in patients with reticular pseudodrusen, and to reduce the progression of RPD to atrophy.\n\nApproximately 50 naïve patients with reticular pseudodrusen who underwent subthreshold laser treatment in perifoveal area. These patients should be randomized in the 2 study arms of the study. Patients will be evaluated at Screening\u002FBaseline and then revaluated and retreated at month 3, 6 and 9. At month 12, all patients will be evaluated with a full ocular examination, visual acuity measurement (VA), optical coherence tomography (OCT) with autofluorescence, OCT-angiography and microperimetry.\n\nThe rationale of the study is to prevent the evolution of reticular pseudodrusen to atrophic degeneration.",[62,63,64,27],"Macular Degeneration, Senile","Laser Burn of Retina","Macular Degeneration Intermediate",[66,67,68,69],"Retina","Age-related macular degeneration","Reticular pseudodrusen","Sub-threshold laser","2025-03-11",{"date":72,"type":40},"2025-03-12",{"date":74,"type":40},"2021-03-16",{"date":76,"type":21},"2026-09-01",{"name":78,"class":47},"Ospedale San Raffaele",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100471388","observation-of-the-natural-course-of-age-related-macular-degeneration-100471388","NCT05418231","Observation of the Natural Course of Age-related Macular Degeneration","Observation of the Natural Course of Dry Age-related Macular Degeneration","Inclusion Criteria:\n\n* 50-85 yrs male or female AMD patients\n* Dry-AMD patients in either early, intermediate, or intermediate-to-late stage confirmed by fundus examinations.\n\nExclusion Criteria:\n\n* Any eye with disease that would interfere with the retinal examinations\n* Research eye with CNV or high myopia\n* Surgeries that may interfere with AMD evaluation\n* Long-term uses of medications that are associated with retinal or neural toxicities.\n* IOP more than 26 mmHg\n* Received cataract surgery in 3 months.\n* Other conditions: diseases that causes less than 5 years survival; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer.\n* Other conditions not suitable for the current study","50 Years","85 Years",{"count":89,"type":21},500,"OBSERVATIONAL","This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a biological sample library of dry AMD mainly in China.",[93,27],"Dry Age-related Macular Degeneration","NOT_YET_RECRUITING","2022-06-09",{"date":97,"type":40},"2022-06-14",{"date":99,"type":21},"2022-07",{"date":101,"type":21},"2027-07",{"name":103,"class":47},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]